IC Targets AS completes last patient visit in Phase 2A mangafodipir trial

IC Targets AS announced that the last patient has completed the study protocol in its Phase 2A clinical trial evaluating mangafodipir-enhanced cardiac Magnetic Resonance Imaging (MRI) in patients with heart failure. This breakthrough imaging approach is designed to provide unprecedented insights into myocardial function and dynamics, with the potential to significantly advance cardiac diagnostics and treatment monitoring.

The overall objective of this open-label Phase 2A Proof-of-Concept trial is to assess the efficacy and safety of mangafodipir-enhanced MRI for the evaluation of myocardial calcium channel activity in patients with heart failure with preserved ejection fraction (HFpEF) caused by hypertrophic cardiomyopathy or cardiac amyloidosis. HFpEF affects millions of people worldwide and remains particularly challenging to diagnose and manage due to its complex pathophysiology, underscoring the need for advanced diagnostic tools. The trial is being conducted at Oslo University Hospital (OUS), Norway, under the leadership of Professor Thor Edvardsen, MD, PhD.

A total of 44 participants, including healthy volunteers and HFpEF patients, were enrolled in the trial. Reaching Last Patient Last Visit (LPLV) marks an important milestone, as all participants have now completed the full trial schedule. The study team will now proceed with final data cleaning and analysis.

“This milestone represents a key step in the clinical process, and we look forward to completing image and data analysis for this important trial in the coming weeks,” said Christina Abrahamsberg, Chief Operating Officer.

IC Targets AS extends its sincere gratitude to all participants, clinical investigators, and study staff whose contributions made this trial possible.